SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

Part of paid clinical trials in Rochester, Minnesota.

Sponsor: Mayo Clinic
Study ID: NCT07850284
Status: Recruiting

Apply to this trial

Conditions

AL Amyloidosis
Multiple Myeloma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Non-Interventional Study — OTHER
Non-interventional study

Study Details

This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.

Key Dates

First listed: Sep 30, 2026
Start date: Aug 25, 2026
Status verified: Sep 2026
Primary completion: Aug 25, 2028
Completion: Aug 25, 2028

Study Design

Enrollment: 150 participants (estimated)

Arms

Arm: Observational
Patients are enrolled in the Quality of life text message system and receive SMS text messages and complete questionnaires daily for 3 months on study.